UroGen Pharma Ltd. (URGN)
40.90
-0.45
(-1.09%)
USD |
NASDAQ |
Sep 28, 16:00
40.90
0.00 (0.00%)
After-Hours: 18:11
UroGen Pharma Research and Development Expense (TTM) : 61.26M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 61.26M |
| March 31, 2026 | 62.83M |
| December 31, 2025 | 67.11M |
| September 30, 2025 | 67.69M |
| June 30, 2025 | 65.03M |
| March 31, 2025 | 61.52M |
| December 31, 2024 | 57.14M |
| September 30, 2024 | 53.55M |
| June 30, 2024 | 52.43M |
| March 31, 2024 | 48.61M |
| December 31, 2023 | 45.61M |
| September 30, 2023 | 48.79M |
| June 30, 2023 | 51.65M |
| March 31, 2023 | 52.71M |
| December 31, 2022 | 52.91M |
| September 30, 2022 | 51.51M |
| June 30, 2022 | 50.34M |
| Date | Value |
|---|---|
| March 31, 2022 | 49.82M |
| December 31, 2021 | 47.64M |
| September 30, 2021 | 46.35M |
| June 30, 2021 | 44.14M |
| March 31, 2021 | 39.65M |
| December 31, 2020 | 45.27M |
| September 30, 2020 | 53.57M |
| June 30, 2020 | 53.34M |
| March 31, 2020 | 55.70M |
| December 31, 2019 | 49.30M |
| September 30, 2019 | 40.67M |
| June 30, 2019 | 40.76M |
| March 31, 2019 | 39.04M |
| December 31, 2018 | 36.93M |
| September 30, 2018 | 32.23M |
| June 30, 2018 | 28.28M |
| March 31, 2018 | 23.66M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Xencor, Inc. | 255.76M |
| MeiraGTx Holdings Plc | 153.16M |
| Insmed, Inc. | 860.84M |
| Ironwood Pharmaceuticals, Inc. | 86.86M |
| Viking Therapeutics, Inc. | 509.32M |